Key Takeaways IRWD's growth is driven by its U.S. Linzess partnership with ABBV, which posted robust Q3 resultsStronger Linzess demand led IRWD to lift its 2025 revenue outlook following a solid Q3 performance.PBYI's Nerlynx posted $144.2M sales in the first nine months of 2025, up 2.5% year over year.Both Ironwood Pharmaceuticals (IRWD) and Puma Biotechnology (PBYI) are small biotechs, concentrating on the successful commercialization of their respective products with the goal of establishing leadership in ...